Bio/Pharma News

Oct 23, 2017
By Pharmaceutical Technology Editors
The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.
Oct 20, 2017
By Pharmaceutical Technology Editors
The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.
Oct 20, 2017
By Pharmaceutical Technology Editors
This approval marks the second gene therapy to be approved by FDA and the first to be approved for certain types of non-Hodgkin lymphoma.
Oct 16, 2017
By Pharmaceutical Technology Editors
The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.
Oct 16, 2017
By Pharmaceutical Technology Editors
Stelara (ustekinumab), already approved for treating adults, is now also approved for treating adolescents with moderate to severe plaque psoriasis.
Oct 16, 2017
By Pharmaceutical Technology Editors
Through the support of the Japanese agency, Daiichi Sankyo intends to further develop its genetic vaccine platform focused around its new nucleic acid delivery technology.
Oct 16, 2017
By Pharmaceutical Technology Editors
The new center will serve as a regional hub where scientists and engineers can work with customers for biological development.
Oct 13, 2017
By Pharmaceutical Technology Editors
The committee has voted unanimously to approve Spark Therapeutics’ gene therapy candidate, Luxturna (voretigene neparvovec), for treating a genetically inherited blindness.
Oct 13, 2017
By Pharmaceutical Technology Editors
Baxter and FDA are working together to prevent shortages of the company’s sodium chloride 0.9% injection bags after recent hurricanes damaged the island.
Oct 12, 2017
By Pharmaceutical Technology Editors
NIH has entered a five-year, $215-million collaboration with leading biopharmaceutical companies to advance the development of cancer immunotherapies.
native1_300x100
lorem ipsum